Press Releases

INVESTIGATIONAL SUBCUTANEOUS FORMULATION CLEARS 14% MORE PLAQUE THAN IV, PHARMACOKINETICS (AUC) 11% HIGHER, AND SIMILAR ARIA RATES TO IV 76% OF PATIENTS SHOWED NO DECLINE AND 60% SHOWED CLINICAL...

Eisai Inc. and Biogen Inc. are honored to announce today that TIME has selected LEQEMBI® (lecanemab-irmb) as one of the Best Inventions of 2023 in the Medical Care category. LEQEMBI is the first...

Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present new data from the phase 3 Clarity AD study for its Alzheimer's disease (AD) treatment...

Data from the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Provide Valuable Information About the Treatment of Patients with Advanced Renal Cell Carcinoma and Certain Types of Advanced...

Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness NUTLEY, N.J., Aug. 17, 2023 /PRNewswire/ -- Eisai Inc., the United States-based pharmaceutical subsidiary of Eisai...